✦ LIBER ✦

Exploring the curative potential of BCR–ABL1-targeting drugs for chronic myeloid leukaemia

✍ Scribed by Peter Valent

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Guidelines for the measurement of BCR-AB

✍ Letizia Foroni; Gill Wilson; Gareth Gerrard; Joanne Mason; David Grimwade; Helen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

Second generation inhibitors of BCR-ABL

✍ Weisberg, Ellen; Manley, Paul W.; Cowan-Jacob, Sandra W.; Hochhaus, Andreas; Gri 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 651 KB

Quantitative monitoring of BCR/ABL1 muta

✍ S. Preuner; G. Mitterbauer; C. Mannhalter; S. Herndlhofer; W.R. Sperr; P. Valent 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 290 KB

Expression of angiogenic factors in chro

✍ C. Sillaber; M. Mayerhofer; K. J. Aichberger; M.-T. Krauth; P. Valent 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB

Off-target effects of BCR–ABL1 inhibitor

✍ Steegmann, Juan Luis; Cervantes, Francisco; le Coutre, Philipp; Porkka, Kimmo; S 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 309 KB

The type of BCR/ABL junction does not pr

✍ Alfonso Zaccaria; Giovanni Martinelli; Marina Buzzi; Nicoletta Testoni; Patrizia 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 402 KB